Zelira Therapeutics’ cannabinoid medicine for chronic insomnia, Zenivol, will now be available for prescription to patients in Australia through the Therapeutic Goods Administration Special Access Scheme.
The Australian launch is a key milestone in commercialising Zenivol, a leading proprietary cannabinoid medicine supported by clinical trial data in patients with chronic insomnia, in global markets.
Zenivol is available for immediate supply via Zelira’s national distribution partner Health House.
Zelira managing director, Dr Richard Hopkins, said: “Zelira is delighted to launch Zenivol in the Australian market as a leading clinically validated cannabinoid-based treatment for chronic insomnia.
“Zenivol is custom designed to address the large unmet need for insomnia patients that have failed current medications and are looking for a safe and effective alternative,” he added.
Zelira remains on-track to complete the launch of five new products in global markets in 2020.
